Skip to content

RANDOMIZED CLINICAL TRIAL COMPARING TRANSURETHRAL PROSTATE RESECTION (TURP) AND ECHOLASER SORACTELITE-TPLA (TRANSPERINEAL LASER ABLATION) IN PATIENTS WITH LOWER URINARY TRACT SYMPTOMS DUE TO BENIGN PROSTATIC OBSTRUCTION

RANDOMIZED CLINICAL TRIAL COMPARING TRANSURETHRAL PROSTATE RESECTION (TURP) AND ECHOLASER SORACTELITE-TPLA (TRANSPERINEAL LASER ABLATION) IN PATIENTS WITH LOWER URINARY TRACT SYMPTOMS DUE TO BENIGN PROSTATIC OBSTRUCTION

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07289243
Enrollment
80
Registered
2025-12-17
Start date
2024-07-14
Completion date
2026-12-25
Last updated
2025-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

RANDOMIZED

Brief summary

THIS STUDY IS A RANDOMIZED CLINICAL TRIAL COMPARING TRANSURETHRAL PROSTATE RESECTION (TURP) AND ECHOLASER SORACTELITE-TPLA (TRANSPERINEAL LASER ABLATION) IN PATIENTS WITH LOWER URINARY TRACT SYMPTOMS DUE TO BENIGN PROSTATIC OBSTRUCTION. THE PRIMARY GOAL IS TO SHOW THE NON-INFERIORITY OF TPLA VERSUS TURP BY IPSS-SCORE.

Interventions

PROCEDUREECHOLASER-TPLA

transperineal laser ablation of prostatic adenoma, by transrectal ultrasound guide.

PROCEDURETURP

Transurethral resection of prostate, by uretrocistoscopy approach.

Sponsors

Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
40 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* age, Lower urinary tract simptoms (IPSS \>= 8), uncompliance or no achived drugs treatment for IPB, prostate volume 40ml-80ml , ability to express informed consent.

Exclusion criteria

* previous surgical tretment for IPB, bladder catheter, bladder stones, urinary or seminal infections, hypo-/a-contractilitis of bladder, bladder tuomrs, urethral stricture, neurological bladder, refuse to sign informed consent

Design outcomes

Primary

MeasureTime frame
IS TO SHOW THE NON-INFERIORITY OF TPLA VERSUS TURP BY IPSS-SCOREone, three, six, twelve mounth after treatment

Secondary

MeasureTime frame
COMPARE Q-MAX UROFLOWone, three, six, twelve mounth after treatment
COMPARE INPATIENT-TIMINGone, three, six, twelve mounth after treatment

Countries

Italy

Contacts

Primary ContactMarcello MZ Zingarelli, medicine and surgery
marcellozingarelli86@gmail.com+393405135446

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026